Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma

被引:14
作者
Peters, Mary Linton B. [1 ]
Stobie, Lindsey [1 ]
Dudley, Beth [2 ]
Karloski, Eve [2 ]
Allen, Kyle [3 ]
Speare, Virginia [3 ]
Dolinsky, Jill S. [3 ]
Tian, Yuan [3 ]
DeLeonardis, Kim [1 ]
Krejdovsky, Jill [1 ]
Button, Arlene [4 ]
Lim, Cynthia [4 ]
Borazanci, Erkut [4 ]
Brand, Randall [2 ]
Tung, Nadine [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, 330 Brookline Ave,Shapiro 913, Boston, MA 02215 USA
[2] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA
[3] Ambry Genet, Div Bioinformat, Div Clin Affairs, Aliso Viejo, CA USA
[4] HonorHlth Res Inst, Scottsdale, AZ USA
关键词
attitude to health; genetic testing; Multidimensional Impact of Cancer Risk Assessment (MICRA); pancreatic ductal carcinoma; CANCER PREDISPOSITION GENES; OVARIAN-CANCER; MUTATIONS; BRCA1; IDENTIFICATION; PREVALENCE; MANAGEMENT; RELATIVES; IMPACT; RISK;
D O I
10.1002/cncr.32077
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Germline genetic testing currently is recommended for patients with pancreatic ductal adenocarcinoma (PDAC). In the current study, the authors assessed how often results are communicated to first-degree relatives within 3 months and the emotional impact of testing on patients. Methods A total of 148 patients who were newly diagnosed with PDAC and who had undergone testing of 32 cancer susceptibility genes at 3 academic centers were selected; 71% participated. Subjects completed the Multidimensional Impact of Cancer Risk Assessment (MICRA) and a family communication survey. The results of both surveys were assessed at 3 months according to the genetic test result (positive, negative, or variant of unknown significance [VUS]) and whether a patient met criteria for genetic testing. Results A total of 99 patients completed the MICRA survey and 104 completed the family communication survey. The average age of the patients was 67 years, 47% were female, 29% had stage III/IV (AJCC 8th edition) disease, and 42% met genetic testing criteria. Approximately 80% of patients told at least 1 first-degree relative about their result. There was a trend toward greater disclosure among patients who tested positive (93% vs 77% for those with a VUS result [P = .149] and 74% for those who tested negative [P = .069]). Patients not meeting genetic testing criteria were less likely to disclose results (69% vs 93%; P = .003). MICRA scores did not differ by test result, age, stage of disease, or sex. Conclusions The rate of result communication was high, although it was lower among patients who did not meet genetic testing criteria, those who tested negative, or those who had a VUS result. Testing-associated distress was similar across patient groups, and was comparable to that reported by other patients with cancer. Improved communication for all patients is crucial given the prognosis of PDAC, which limits time for disclosure.
引用
收藏
页码:2488 / 2496
页数:9
相关论文
共 34 条
[1]  
[Anonymous], Genetic/familial high-risk asssessment: Breast and ovarian
[2]   Peutz-Jeghers syndrome: a systematic review and recommendations for management [J].
Beggs, A. D. ;
Latchford, A. R. ;
Vasen, H. F. A. ;
Moslein, G. ;
Alonso, A. ;
Aretz, S. ;
Bertario, L. ;
Blanco, I. ;
Bulow, S. ;
Burn, J. ;
Capella, G. ;
Colas, C. ;
Friedl, W. ;
Moller, P. ;
Hes, F. J. ;
Jarvinen, H. ;
Mecklin, J-P ;
Nagengast, F. M. ;
Parc, Y. ;
Phillips, R. K. S. ;
Hyer, W. ;
de Leon, M. Ponz ;
Renkonen-Sinisalo, L. ;
Sampson, J. R. ;
Stormorken, A. ;
Tejpar, S. ;
Thomas, H. J. W. ;
Wijnen, J. T. ;
Clark, S. K. ;
Hodgson, S. V. .
GUT, 2010, 59 (07) :975-986
[3]   Psychological distress related to BRCA testing in ovarian cancer patients [J].
Bjornslett, Merete ;
Dahl, Alv A. ;
Sorebo, Oystein ;
Dorum, Anne .
FAMILIAL CANCER, 2015, 14 (04) :495-504
[4]   Colorectal cancer in the family: Psychosocial distress and social issues in the years following genetic counselling [J].
Bleiker, Eveline M. A. ;
Menko, Fred H. ;
Kluijt, Irma ;
Taal, Babs G. ;
Gerritsma, Miranda A. ;
Wever, Lidwina D. V. ;
Aaronson, Neil K. .
HEREDITARY CANCER IN CLINICAL PRACTICE, 2007, 5 (02) :59-66
[5]   Prospective Study of Germline Genetic Testing in Incident Cases of Pancreatic Adenocarcinoma [J].
Brand, Randall ;
Borazanci, Erkut ;
Speare, Virginia ;
Dudley, Beth ;
Karloski, Eve ;
Peters, Mary Linton B. ;
Stobie, Lindsey ;
Bahary, Nathan ;
Zeh, Herbert ;
Zureikat, Amer ;
Hogg, Melissa ;
Lee, Kenneth ;
Tsung, Allan ;
Rhee, John ;
Ohr, James ;
Sun, Weijing ;
Lee, James ;
Moser, A. James ;
DeLeonardis, Kim ;
Krejdovsky, Jill ;
Dalton, Emily ;
LaDuca, Holly ;
Dolinsky, Jill ;
Colvin, Arlene ;
Lim, Cynthia ;
Black, Mary Helen ;
Tung, Nadine .
CANCER, 2018, 124 (17) :3520-3527
[6]   A brief assessment of concerns associated with genetic testing for cancer: The Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire [J].
Cella, D ;
Hughes, C ;
Peterman, A ;
Chang, CH ;
Peshkin, BN ;
Schwartz, MD ;
Wenzel, L ;
Lemke, A ;
Marcus, AC ;
Lerman, C .
HEALTH PSYCHOLOGY, 2002, 21 (06) :564-572
[7]   Sensitivity and predictive value of criteria for p53 germline mutation screening [J].
Chompret, A ;
Abel, A ;
Stoppa-Lyonnet, D ;
Brugières, L ;
Pagès, S ;
Feunteun, J ;
Bonaïti-Pellié, C .
JOURNAL OF MEDICAL GENETICS, 2001, 38 (01) :43-47
[8]   Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers [J].
de Bono, Johann ;
Ramanathan, Ramesh K. ;
Mina, Lida ;
Chugh, Rashmi ;
Glaspy, John ;
Rafii, Saeed ;
Kaye, Stan ;
Sachdev, Jasgit ;
Heymach, John ;
Smith, David C. ;
Henshaw, Joshua W. ;
Herriott, Ashleigh ;
Patterson, Miranda ;
Curtin, Nicola J. ;
Byers, Lauren Averett ;
Wainberg, Zev A. .
CANCER DISCOVERY, 2017, 7 (06) :620-629
[9]   Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations [J].
Finlay, Esme ;
Stopfer, Jill E. ;
Burlingame, Eric ;
Evans, Katherine Goldfeder ;
Nathanson, Katherine L. ;
Weber, Barbara L. ;
Armstrong, Katrina ;
Rebbeck, Timothy R. ;
Domchek, Susan M. .
GENETIC TESTING, 2008, 12 (01) :81-91
[10]   Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].
Fong, Peter C. ;
Boss, David S. ;
Yap, Timothy A. ;
Tutt, Andrew ;
Wu, Peijun ;
Mergui-Roelvink, Marja ;
Mortimer, Peter ;
Swaisland, Helen ;
Lau, Alan ;
O'Connor, Mark J. ;
Ashworth, Alan ;
Carmichael, James ;
Kaye, Stan B. ;
Schellens, Jan H. M. ;
de Bono, Johann S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134